About Us

Our History

2000
WuXi PharmaTech was registered in the city of Wuxi, Jiangsu and operated in Shanghai
2001
WuXi started synthetic chemistry services
2003
WuXi started manufacturing process development services
2004
WuXi started manufacturing services for research and development
2005
WuXi started bio-analytical services
2006
WuXi started antibody discovery and process development services
2007
WuXi started toxicology and formulation services
The Tianjin site of WuXi was put into operation and it was among the leading R&D bases of chemical medicines in China then
WuXi PharmaTech traded on the New York Stock Exchange under the ticker symbol "NYSE:WX"
WuXi set up "Life Science and Chemistry Awards", aiming to stimulate early-stage innovation and promote excellence in life sciences and clinical research
2008
WuXi PharmaTech acquired AppTec Laboratory Services. The Company has been renamed WuXi AppTec since then
2009
WuXi opened a toxicology facility in Suzhou, which became the most important base of toxicology services
2010
SynTheAll Pharmaceutical (STA) opened a large-scale manufacturing facility in Jinshan District, Shanghai
2011
WuXi acquired Medkey, expanding to clinical development and registration services
2012
The R&D and manufacturing site in the city of Wuxi was put into operation
Wuhan site was put into operation, and it became the key of WuXi's strategic network in central and western China
2014
WuXi AppTec opened a new plant in Philadelphia of USA, focusing on R&D and production services of CAR-T therapies and other immunotherapies
WuXi Laboratory Testing Division expanded in U.S. with acquisition of XenoBiotic Laboratories, bolstering LTD's bioanalytical and DMPK/ADME services
2015
SynTheAll Pharmaceutical (STA) listed its shares on the New Third Board
WuXi launched medical device testing services in China
2016
WuXi acquired Crelux, enhancing WuXi's structure-based drug discovery capabilities in Europe
STA began operations at a new, fully integrated R&D and cGMP manufacturing site in Changzhou
2017
WuXi set up Advanced Therapy Unit in the US, focusing on cell and gene therapies
WuXi acquired HD Biosciences, strengthening WuXi's biology R&D capacity and capability
WuXi acquired ResearchPoint Global, expanding WuXi's clinical research capabilities worldwide
2018
WuXi built up its Life Science Industry Park in Chengdu
WuXi AppTec announced listing of Initial Public Offering of Common Stock on the Shanghai Stock Exchange (stock code: 603259.SH)
WuXi AppTec listed H shares on the Hong Kong Stock Exchange (stock code: 2359.HK)
2019
The first WuXi Healthcare Forum held in Shanghai
WuXi AppTec acquired Pharmapace to enhance biometrics services for clinical development